There are currently 85 clinical trials in Bakersfield, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Comprehensive Blood and Cancer Center, GSK Investigational Site, AIS Cancer Center at San Joaquin Community Hospital and California Retina Consultants. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Efficacy of Faricimab in Patients With NPDR
Recruiting
The purpose of this Phase 2 study is comprised of two groups to evaluate the safety, tolerability, and efficacy of faricimab in patients with Non-Proliferative Diabetic Retinopathy.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: California Retina Consultants, Bakersfield, California
Conditions: Non-Proliferative Diabetic Retinopathy
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
Recruiting
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 120 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjec... Read More
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
09/22/2023
Locations: Kern Research, Bakersfield, California
Conditions: Bilateral Nasal Polyposis
Accuracy of IOLMASTER 700 Total Keratometry (TK)
Recruiting
This is a multicenter study to compare the accuracy of IOL calculations in post-laser vision corrected eyes that are about to undergo or have undergone cataract surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Empire Eye & Laser Center, Bakersfield, California
Conditions: Myopia, Hyperopia, Cataract
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Recruiting
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, b... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
08/17/2023
Locations: California Retina Consultants, Bakersfield, California
Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
Recruiting
This is a phase 3 study to compare the efficacy and safety of HBI-8000 or Placebo combined with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who are not adolescents or patients with new, progressive brain metastasis will be stratified by PD-L1 expression and LDH level.
Gender:
All
Ages:
12 years and above
Trial Updated:
07/25/2023
Locations: Comprehensive Blood and Cancer Center, Bakersfield, California
Conditions: Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
Recruiting
The study aims at evaluating the maintenance of virologic suppression of dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC) at Week 48 post-switch from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in participants living with Human Immunodeficiency Virus Type 1 (HIV-1) who are of at least 50 years of age and above.
Gender:
All
Ages:
50 years and above
Trial Updated:
07/17/2023
Locations: GSK Investigational Site, Bakersfield, California
Conditions: HIV
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
Recruiting
This is a multicentre study carried out in participants living with human immunodeficiency virus type 1 (HIV-1) who have not previously been treated with any antiretroviral therapies. The study will investigate two 2-drug regimens for the treatment of HIV-1: a fixed-dose combination oral tablet of dolutegravir/lamivudine (DTG/3TC) and cabotegravir plus rilpivirine long-acting agents (CAB + RPV LA). All participants will initially receive DTG/3TC once daily, and once virologic suppression is atta... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/17/2023
Locations: GSK Investigational Site, Bakersfield, California
Conditions: HIV Infections
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Recruiting
This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
Gender:
Female
Ages:
Between 45 years and 74 years
Trial Updated:
06/21/2023
Locations: Kern Radiology Medical Group Inc, Bakersfield, California
Conditions: Breast Screening
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Recruiting
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for tre... Read More
Gender:
All
Ages:
Between 50 years and 89 years
Trial Updated:
05/18/2023
Locations: Bakersfield Location, Bakersfield, California
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME)
Recruiting
RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of diabetic retinopathy, a chronic and progressive complication of diabetes mellitus. Diabetic retinopathy (DR) is a sight-threatening disease characterized in the early stages by neuronal and vascular dysfunction in the retina, and later by neovascularization that leads to further deterioration of functional vision. Despite the availability of current treatments, diabetic retinopathy remains the l... Read More
Gender:
All
Ages:
Between 25 years and 89 years
Trial Updated:
05/18/2023
Locations: California Retina Consultants, Bakersfield, California
Conditions: Diabetic Retinopathy (DR)
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
Recruiting
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
Gender:
All
Ages:
16 years and above
Trial Updated:
11/30/2022
Locations: Valley Fever Institute at Kern Medical Center, Bakersfield, California
Conditions: Invasive Fungal Infections